Finally, Nicholas Casey published recently a paper on the use of RNAi with TCR transfer to enhance safety and efficiency. Follow the guide!
We participated to the EATRIS annual meeting in Lisbon and presented our work. We thank all the team for their great work and their commitment in this infrastructure.
A recent article in Nature Immunology showed a new type of T-cells that could improve cell-based therapies.
Forskning has asked Else Marit her opinion about it and about the latest developments in this field. Make sure to have a look here!
A new review from Else Marit Inderberg and Sebastien Wälchli was published in Cancer Immunology, Immunotherapy. The review described how we can isolate and identify therapeutic TCRs from long-term surviving patients.
Make sure to have a look here!
Amanda Ruud defended her Master at the University of Oslo, Wednesday (18/12). Her thesis title was: "Identification and pre-clinical assessment of patient-derived TCRs for solid tumor immunotherapy"
Pierre won the award with his talk entitled: "Targeting telomerase with an MHC class II restricted TCR for cancer immunotherapy". Make sure to have a look at his abstract!
We will be at the annual NSI meeting, the 29th of November!
We will talk about our latest progress on CAR and TCR therapy. See you there!
Sebastien Wälchli was invited at the 1st meeting ASEICA-ASPIC on Immunotherapy to talk about TCR based ACT.
Sebastien Walchli, a group leader in our department, gave an interview to the technical transfer office of the hospital: Inven2.
Make sure to check it here !
Emmanuelle Benard will present our last improvements on CD37 CAR T-cell therapy. Make sure to check the program of the conference and her abstract !
Nadia Mensali and Marit R. Myhre published a new study entitled: "Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy". A copy of the study published in Cancer Immunology, Immunotherapy can be found here.
We were at the last PIVAC (Progress in Vaccination Against Cancer) 2019 !
Else Marit and Hedvig presented our most recent developments !
Make sure to check their abstracts !
Yesterday Lizet Baken successfully defended her Bachelor Thesis at the Avans University of Applied Sciences.
Part of this thesis was performed in our lab where she has been working on an anti-Ig-lambda CAR.
Congratulations Lizet, we are all very proud of you!
Our collaborators published a new paper on TIGIT and PD-1 as markers of reduced effector function of T-cells in B-cell lymphoma.
Make sure to have a look here !
Gunnar Kvalheim, Hakan Köksal and Pierre Dillard will be at the next AACR meeting (29th of March to 3rd of April, Atalanta) to talk about new developments in CAR.
Hakan will present a novel combination method for IGKCAR that prevents B-cell aplasia.
Pierre will present the pre-clinical validation of CD37CAR, an alternative to CD19CAR.
Make sure to have a look!
Pierre Dillard will present our rescent work on the pre-clinical validation of CD37 CAR T-cells in Barcelona (11 - 13 March 2019).
Make sure to take a look at the abstract and at the conference website !
We published a new paper on redirected NK cells, transduced with TCR.
Make sure to take a look at the paper here !
New publication from Nadia Mensali in OncoImmunology.
This article decribe the loading of MCHI and II molecules by using CD74 constructs.
Make sure to check it out here!
We published a new review on the treatment of osteosarcoma by CAR therapy.
Make sure to have a looke here !
We published a new protocol on the assessment of CAR activity by spheroids. Have a look at our paper here and on the OCCi website news.
Emmanuelle Benard who did her PhD in Biophysics and Immunology in Marseille, just joined us !
She will be in charge of the development of new CAR T-cells.
We had our first JOVE shooting on a new metod to generate spheroid for CAR T-cells screening.
Make sure to give it a look (once it is out) !
PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy.
